WO2005110443A1 - Antiviral agent - Google Patents

Antiviral agent Download PDF

Info

Publication number
WO2005110443A1
WO2005110443A1 PCT/JP2005/008758 JP2005008758W WO2005110443A1 WO 2005110443 A1 WO2005110443 A1 WO 2005110443A1 JP 2005008758 W JP2005008758 W JP 2005008758W WO 2005110443 A1 WO2005110443 A1 WO 2005110443A1
Authority
WO
WIPO (PCT)
Prior art keywords
antiviral agent
sbw
polyacid
antiviral
herpes virus
Prior art date
Application number
PCT/JP2005/008758
Other languages
French (fr)
Japanese (ja)
Inventor
Toshihiro Yamase
Yoko Shoji
Original Assignee
The Circle For The Promotion Of Science And Engineering
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Circle For The Promotion Of Science And Engineering filed Critical The Circle For The Promotion Of Science And Engineering
Publication of WO2005110443A1 publication Critical patent/WO2005110443A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • the present invention relates to a novel antiviral agent.
  • the antiviral agent of the present invention is a highly safe antiviral agent because it contains a low cytotoxic V-polyacid as an active ingredient.
  • Acyclovir (Acyclovir, ACV) developed by Elion et al. Has a strong antiviral effect and relatively few side effects, and is therefore widely used as an anti-herpesvirus agent. Although acyclovir is an excellent drug, it has problems such as the emergence of resistant viruses when used for a long period of time.
  • the present inventor has proposed polyacids such as [Eu (MoO) (HO) (MoO)] and [(SbWO) VO].
  • Patent Documents 1 and 2 It has been found that it has antiviral activity against several viruses, including the NK virus, and has filed applications based on this finding (Patent Documents 1 and 2). However, the antiviral action of these polyacid ions was not always strong.
  • Patent Document 1 JP-A-5-320059
  • Patent Document 2 JP-A-2000-229864
  • Patent Document 3 JP-A-8-73362
  • the present invention has been made under the above-mentioned technical background, and has an object to provide a polyacid having a stronger antiviral effect.
  • a polyacid ion represented by the formula (1): [SbW 0] or a salt thereof is contained as an active ingredient.
  • the antiviral agent of the present invention has a polyacid ion represented by the formula: [SbW 0] or a salt thereof.
  • Patent Document 3 It has been known that the above polyacid ions and the like have an anti-MRSA action (Patent Document 3), but it has been first revealed for the first time that they have an extremely high antiviral action.
  • a salt of a polyacid ion represented by the formula: [SbW O] has an antiviral effect.
  • salt comprising at least one cation selected from the group consisting of guanidinium.
  • this salt may contain water of crystallization in the molecule. Specific examples of such salts include Na [SbW O
  • polyacid ions and salts thereof can be prepared by known methods, for example, Tourne C, Revel A.,
  • the method of administering the antiviral agent of the present invention is not particularly limited, and can be administered by a method such as oral administration, administration by injection, or application to the skin or the like, similarly to known antiviral agents.
  • Various dosage forms can be selected according to the administration method, and for example, dosage forms such as injections, tablets, granules, ointments and the like can be taken.
  • the content of the polyacid ion and the like in the antiviral agent of the present invention varies depending on the administration method, dosage form, and the like, but is usually about 0.1 to 20% (weight).
  • the dosage also varies depending on the dosage form and the like, but it is usually preferable to administer about 100 to 3000 mg per day to an adult.
  • the antiviral agent of the present invention may contain another antiviral substance (eg, a polyacid ion other than the above polyacid ion) in addition to the above polyacid ion! / ,.
  • another antiviral substance eg, a polyacid ion other than the above polyacid ion
  • the type of virus targeted by the antiviral agent of the present invention is not particularly limited, but it is more preferable to target simple herpes virus, which is preferable to target herpes virus. Most preferably, the target is simple herpes virus type 1 (HSV-1).
  • HSV-1 simple herpes virus type 1
  • the novel antiviral agent provided by the present invention has low cytotoxicity and high safety because polyacid is an effective component.
  • the aqueous solution was added and the mixture was kept at 80-90 ° C for about 1 hour. At this time, the pH of the aqueous solution was 7.0 to 7.5. After cooling to room temperature, the obtained crystals were washed with water, dried and then subjected to X-ray structure analysis. As a result, it was confirmed that the crystal was Na [SbW O] ⁇ 19.5.
  • Vero cells obtained from Flow Laboratories, Inc., USA
  • HSV-1 obtained from KOS strain, Institute of Medical Science, University of Tokyo
  • Titer 100 pfo
  • test substances Na [SbW O] ⁇ 19.5H O, 16 kinds of polyacid salts, and
  • ACV which is an antiviral agent used in this study, was used.
  • the antiviral activity is determined by the concentration (EC, 50%
  • the cytotoxicity was expressed as a 50% cytotoxic concentration (CC, 50% cytotoxic concentration) of the test substance.
  • CC 50% cytotoxic concentration
  • the CC / EC must be
  • “ ⁇ ” indicates that the value was larger than the value shown in the table
  • “>” indicates that the value was smaller than the value shown in the table.
  • “-” Indicates that toxicity was so high that CC ; () could not be measured.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel antiviral agent as a replacement for antiviral agent containing acyclovir, or a polyacid ion such as [Eu4(MoO4)(H2O)16(Mo7O24)4]p- or [(SbW9O33)2V3O3]p-, which novel antiviral agent comprises as an active ingredient a polyacid ion of the formula [SbW9O33]9- or its salt.

Description

抗ウィルス剤  Antiviral agent
技術分野  Technical field
[0001] 本発明は、新規な抗ウィルス剤に関する。本発明の抗ウィルス剤は、細胞毒性の低 Vヽポリ酸を有効成分とするため、安全性の高!、抗ウィルス剤である。  [0001] The present invention relates to a novel antiviral agent. The antiviral agent of the present invention is a highly safe antiviral agent because it contains a low cytotoxic V-polyacid as an active ingredient.
背景技術  Background art
[0002] エリオンらによって開発されたァシクロビル (Acyclovir, ACV)は、強力な抗ウィルス 作用を持ち、また、比較的副作用も少ないことから、抗ヘルぺスウィルス剤として広く 用いられている。ァシクロビルは優れた薬剤であるが、長期間使用した場合には耐性 ウィルスが出現するなどの問題もあり、これに代わる新たな抗ヘルぺスウィルス剤の 開発が望まれている。  [0002] Acyclovir (Acyclovir, ACV) developed by Elion et al. Has a strong antiviral effect and relatively few side effects, and is therefore widely used as an anti-herpesvirus agent. Although acyclovir is an excellent drug, it has problems such as the emergence of resistant viruses when used for a long period of time.
[0003] 本発明者は、 [Eu (MoO )(H O) (Mo O ) ] や [(SbW O ) V O ] などのポリ酸ィォ  [0003] The present inventor has proposed polyacids such as [Eu (MoO) (HO) (MoO)] and [(SbWO) VO].
4 4 2 16 7 24 4 9 33 2 3 3  4 4 2 16 7 24 4 9 33 2 3 3
ンカ ヘルぺスウィルスを含む幾つかのウィルスに対し抗ウィルス作用を持つこと見 出し、この知見に基づき先に出願を行っている（特許文献 1、特許文献 2)。しかし、こ れらのポリ酸イオンの抗ウィルス作用は必ずしも強 、ものではなかった。  It has been found that it has antiviral activity against several viruses, including the NK virus, and has filed applications based on this finding (Patent Documents 1 and 2). However, the antiviral action of these polyacid ions was not always strong.
[0004] 特許文献 1：特開平 5-320059号公報 [0004] Patent Document 1: JP-A-5-320059
特許文献 2：特開 2000-229864号公報  Patent Document 2: JP-A-2000-229864
特許文献 3：特開平 8-73362号公報  Patent Document 3: JP-A-8-73362
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0005] 本発明は、上述したような技術的背景の下になされたものであり、より強力な抗ウイ ルス作用を持つポリ酸を提供することを目的とする。 [0005] The present invention has been made under the above-mentioned technical background, and has an object to provide a polyacid having a stronger antiviral effect.
課題を解決するための手段  Means for solving the problem
[0006] 本発明者は、上記課題を解決するため鋭意検討を重ねた結果、式： [SbW 0 ] で [0006] The inventor of the present invention has conducted intensive studies to solve the above-mentioned problems, and as a result, the expression: [SbW 0]
9 33 表されるポリ酸イオンの塩力 単純へルぺスウィルスに対し、他のポリ酸とは比較でき ないほどの強力な抗ウィルス作用を持つことを見出し、この知見に基づき、本発明を 完成するに至った。 [0007] 即ち、本発明は、以下の（1)〜（5)を提供するものである。 9 33 Salt power of polyacid ion represented by the finding that it has a strong antiviral action against simple herpes virus that is incomparable with other polyacids. It was completed. That is, the present invention provides the following (1) to (5).
[0008] (1)式: [SbW 0 ] で表されるポリ酸イオン、又はその塩を有効成分として含有する  [0008] A polyacid ion represented by the formula (1): [SbW 0] or a salt thereof is contained as an active ingredient.
9 33  9 33
抗ウィルス剤。  Antiviral agent.
[0009] (2)式： [SbW 0 ] で表されるポリ酸イオンの塩力 Na [SbW Ο ] · 19.5Η Οである（1)  [0009] The salt force of the polyacid ion represented by the formula (2): [SbW 0] is Na [SbW Ο] · 19.5Η （(1)
9 33 9 9 33 2  9 33 9 9 33 2
記載の抗ウィルス剤。  The antiviral agent according to the above.
[0010] (3)ウィルス力 ヘルぺスウィルスである（1)又は（2)記載の抗ウィルス剤。  (3) Viral power The antiviral agent according to (1) or (2), which is a herpes virus.
[0011] (4)ヘルぺスウィルスが、単純へルぺスウィルスである（3)記載の抗ウィルス剤。 (4) The antiviral agent according to (3), wherein the herpes virus is a simple herpes virus.
[0012] (5)単純へルぺスウィルスが、単純へルぺスウィルス 1型である（4)記載の抗ウィルス 剤。 (5) The antiviral agent according to (4), wherein the simple herpes virus is simple herpes virus 1.
[0013] 以下、本発明を詳細に説明する。  Hereinafter, the present invention will be described in detail.
[0014] 本発明の抗ウィルス剤は、式: [SbW 0 ] で表されるポリ酸イオン、又はその塩を有  The antiviral agent of the present invention has a polyacid ion represented by the formula: [SbW 0] or a salt thereof.
9 33  9 33
効成分として含有するものである。上記ポリ酸イオン等が、抗 MRSA作用を持つことは 既に知られていたが（特許文献 3)、非常に高い抗ウィルス作用を持つことは今回初 めて明らかになつたことである。  It is contained as an active ingredient. It has been known that the above polyacid ions and the like have an anti-MRSA action (Patent Document 3), but it has been first revealed for the first time that they have an extremely high antiviral action.
[0015] 式： [SbW O ] で表されるポリ酸イオンの塩は、抗ウィルス作用を持つものであれば [0015] A salt of a polyacid ion represented by the formula: [SbW O] has an antiviral effect.
9 33  9 33
特に限定されず、例えば、ナトリウム、カリウム、セシウム、カルシウム、ストロンチウム、 ノ リウム、アンモ-ゥム、水素、メチルアンモ-ゥム、ジメチルアンモ-ゥム、トリメチル アンモニゥム、テトラメチルアンモニゥム、ェチルアンモニゥム、ジェチルアンモニゥム 、イソプロピルアンモ-ゥム、ジイソプロピルアンモ-ゥム、プロピルアンモ-ゥム、ジプ 口ピルアンモ-ゥム、ブチルアンモ-ゥム、ジブチルアンモ-ゥム、トリブチルアンモ- ゥム、テトラプチルアンモ-ゥム、及びグァ-ジゥム力もなる群より選ばれる少なくとも 1 種の陽イオンとからなる塩を例示することができる。また、この塩は、分子中に結晶水 を含んでいてもよい。このような塩の具体例としては、 Na [SbW O  There is no particular limitation, for example, sodium, potassium, cesium, calcium, strontium, norium, ammonium, hydrogen, methylammonium, dimethylammonium, trimethylammonium, tetramethylammonium, ethylammonium Arm, getyl ammonium, isopropyl ammonium, diisopropyl ammonium, propyl ammonium, zipper pill ammonium, butyl ammonium, dibutyl ammonium, tributyl ammonium , Tetrabutylammonium, and a salt comprising at least one cation selected from the group consisting of guanidinium. In addition, this salt may contain water of crystallization in the molecule. Specific examples of such salts include Na [SbW O
9 9 331- 19.5H 0、 Na  9 9 331-19.5H 0, Na
2 8 2 8
K[SbW O ] · 19Η 0、 Na K [SbW O ] ·20Η 0、 (NH ) Na[SbW O ] · 19Η 0、 K [SbWK [SbW O] · 19Η0, Na K [SbW O] · 20Η0, (NH) Na [SbW O] · 19Η0, K [SbW
9 33 2 7 2 9 33 2 4 8 9 33 2 9 99 33 2 7 2 9 33 2 4 8 9 33 2 9 9
O 19.5H Oなどを f列示できる。 O 19.5H O etc. can be shown in column f.
33 2  33 2
[0016] 上記ポリ酸イオン及びその塩は、公知の方法、例えば、 Tourne C, Revel A.,  [0016] The polyacid ions and salts thereof can be prepared by known methods, for example, Tourne C, Revel A.,
Tourne G.， Vendrell M., C. R. Acad. Sci., Ser.C, 277., 643-645 (1973)に記載され ている方法などに従って合成することができる。 [0017] 本発明の抗ウィルス剤の投与方法は特に限定されず、既知の抗ウィルス剤と同様 に、経口投与、注射による投与、皮膚等への塗布といった方法によって投与すること ができる。また、剤型は投与方法に応じて様々なものを選択することができ、例えば、 注射剤、錠剤、顆粒剤、軟膏剤などの剤型をとり得る。 It can be synthesized according to the method described in Tourne G., Vendrell M., CR Acad. Sci., Ser. C, 277., 643-645 (1973). [0017] The method of administering the antiviral agent of the present invention is not particularly limited, and can be administered by a method such as oral administration, administration by injection, or application to the skin or the like, similarly to known antiviral agents. Various dosage forms can be selected according to the administration method, and for example, dosage forms such as injections, tablets, granules, ointments and the like can be taken.
[0018] 本発明の抗ウィルス剤中の上記ポリ酸イオン等の含有量は投与方法や剤型などに より異なるが、通常、 0.1〜20% (重量)程度である。また、投与量も剤型等によって異 なるが、 1日当り大人に対し、通常、 100〜3000mg程度投与するのが好ましい。  [0018] The content of the polyacid ion and the like in the antiviral agent of the present invention varies depending on the administration method, dosage form, and the like, but is usually about 0.1 to 20% (weight). The dosage also varies depending on the dosage form and the like, but it is usually preferable to administer about 100 to 3000 mg per day to an adult.
[0019] 本発明の抗ウィルス剤は、上記ポリ酸イオン等のほかに、別の抗ウィルス性物質（ 例えば、上記ポリ酸イオン以外のポリ酸イオンなど）を含んで!/、てもよ!/、。  [0019] The antiviral agent of the present invention may contain another antiviral substance (eg, a polyacid ion other than the above polyacid ion) in addition to the above polyacid ion! / ,.
[0020] 本発明の抗ウィルス剤が対象とするウィルスの種類は特に限定されないが、ヘルべ スウィルスを対象とするのが好ましぐ単純へルぺスウィルスを対象とするのが更に好 ましぐ単純へルぺスウィルス 1型（HSV-1)を対象とするのが最も好ましい。  [0020] The type of virus targeted by the antiviral agent of the present invention is not particularly limited, but it is more preferable to target simple herpes virus, which is preferable to target herpes virus. Most preferably, the target is simple herpes virus type 1 (HSV-1).
発明の効果  The invention's effect
[0021] 本発明によって提供される新規な抗ウィルス剤は、細胞毒性の低 、ポリ酸を有効成 分とするため、安全性が高いものである。  [0021] The novel antiviral agent provided by the present invention has low cytotoxicity and high safety because polyacid is an effective component.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0022] 以下、実施例等により本発明を更に詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to Examples and the like.
[0023] 〔合成例〕 [Synthesis Example]
1.96gの Sb 0 (6.7ミリモル濃度）を 6規定の塩酸水溶液 10mlに溶解させた。次に、  1.96 g of Sb 0 (6.7 mmol) was dissolved in 10 ml of 6N hydrochloric acid aqueous solution. next,
2 3  twenty three
40gの Na WO (120ミリモル濃度）を 80mlの水に溶解、沸騰させた水溶液に前記塩酸 40 g of Na WO (120 mmol) was dissolved in 80 ml of water, and the hydrochloric acid was added to the boiling aqueous solution.
2 4 twenty four
水溶液を加え、混合物を 80〜90°Cに約 1時間保持した。この時水溶液の pHは、 7.0 〜7.5であった。室温まで冷却し、得られた結晶を水洗、乾燥後 X線構造解析を行うと 、Na [SbW O ] · 19.5であることが確認された。  The aqueous solution was added and the mixture was kept at 80-90 ° C for about 1 hour. At this time, the pH of the aqueous solution was 7.0 to 7.5. After cooling to room temperature, the obtained crystals were washed with water, dried and then subjected to X-ray structure analysis. As a result, it was confirmed that the crystal was Na [SbW O] · 19.5.
9 9 33  9 9 33
[0024] 〔実施例〕  [Example]
96穴マイクロタイタープレートに Vero細胞（米国、フローラボラトリーズインコーポレ ーシヨンズより入手）を 1 X 105/wellになるように入れ、これに HSV-1 (KOS株、東京大 学医科学研究所より入手、力価： 100 pfo)と種々の濃度の試験物質を加えた。 COィ Vero cells (obtained from Flow Laboratories, Inc., USA) are placed in a 96-well microtiter plate at 1 × 10 5 / well, and HSV-1 (obtained from KOS strain, Institute of Medical Science, University of Tokyo) , Titer: 100 pfo) and various concentrations of the test substances. CO
2 ンキュベータ一で 37°Cで 4日間培養した後、 MTT法により生存細胞数を調べ、抗ウイ ルス活性と細胞毒性を算出した。 2 After culturing at 37 ° C for 4 days in an incubator, the number of viable cells was determined by the MTT method. Ruth activity and cytotoxicity were calculated.
[0025] 試験物質としては、 Na [SbW O ] · 19.5H Oのほかに、 16種類のポリ酸塩、及び既知 [0025] As test substances, Na [SbW O] · 19.5H O, 16 kinds of polyacid salts, and
9 9 33 2  9 9 33 2
の抗ウィルス剤である ACVを使用した。  ACV, which is an antiviral agent used in this study, was used.
[0026] 抗ウィルス活性は、 HSV感染による細胞傷害を 50%阻止する濃度 (EC 、50% [0026] The antiviral activity is determined by the concentration (EC, 50%
50 effective concentration)で表し、細胞毒性は、試験物質による 50%細胞傷害濃度（ CC 、 50% cytotoxic concentration)で表した。また、 CC /EC を各試験物質の有効 The cytotoxicity was expressed as a 50% cytotoxic concentration (CC, 50% cytotoxic concentration) of the test substance. In addition, the CC / EC must be
50 50 50 50 50 50
係数（SI、 Selectivity Index)とした。  Coefficient (SI, Selectivity Index).
[0027] 以上の結果を表 1に示す。 Table 1 shows the above results.
[0028] [表 1] 試験物質 CC50 EC50 SI [Table 1] Test substance CC50 EC 50 SI
( x g/ml)  (x g / ml)
Na9 [SbW9( . 19. 5H20 619. 71 0. 19 3261. 63Na 9 [SbW 9 (.19.5H 2 0 619.71 0.19 3261.63
K Wl8062] · 15 62. 63 1. 15 54. 31 7 [PT i2W10O40] · 6H20 179. 67 140. 86 1. 28 [PriNH3] 6H [PTi2W,0038 (02) 2] · H20 80. 03 0. 90 88. 80 11H [ (VO) 3 (SbW9033) 2] · 27¾0 223. 75 0. 54 416. 43 [NHJ [ (VO) 3 (SbW9033) 2] · nH20 225. 20 0. 49 456. 48 a -B Na10 [SiW9O34] · 18H20 96. 21 1. 27 75. 66 V0S04 4. 93 KW l8 0 62 ] 15 62.63 1.15 54.31 7 [PTi 2 W 10 O 40 ] 6H 2 0 179.67 140.86 1.28 [PriNH 3 ] 6 H [PTi 2 W, 0 0 38 (0 2 ) 2 ] H 2 0 80.03 0.90 88.80 1 1 H [(VO) 3 (SbW 9 0 33 ) 2 ] 27¾0 223.75 0.54 416.43 [ NHJ [(VO) 3 (SbW 9 33 ) 2 ] nH 2 0 225.20 0.49 456.48 a -B Na 10 [SiW 9 O 34 ] 18H 2 0 96.21 1.27 75. 66 V0S0 4 4.93
Rb4KNa [ (03PCH2COZ) 2Mo5015] · H20 336. 64 99. 58 3. 38 Kl2 [ (VO) 3 (AsW9033) 2] · 17¾0 36. 21 7. 81 4. 63 K12 [ (VO) 3 (BiW,033) 2] · 9¾0 92. 67 101. 71 0. 91 Na12V14B908, Rb 4 KNa [(0 3 PCH 2 CO Z) 2 Mo 5 0 15] · H 2 0 336. 64 99. 58 3. 38 K l2 [(VO) 3 (AsW 9 0 33) 2] · 17¾0 36. 21 7. 81 4. 63 K 12 [ (VO) 3 (BiW, 0 33) 2] · 9¾0 92. 67 101. 71 0. 91 Na 12 V 14 B 9 0 8,
[NH4] l2—x [ (BiW9033) 3Bi6 (OH) 3 (H20) 3V40,J · 25H,0 299. 95 7. 81 38. 39 K sal t of [Sb2W18V4] 29. 14 7. 81 3. 73[NH 4 ] l2 — x [(BiW 9 0 33 ) 3 Bi 6 (OH) 3 (H 2 0) 3 V 40 , J · 25H, 0 299.95 7.81 38.39 K salt of [ Sb 2 W 18 V 4 ] 29.14 7.81 3.73
K„H [ (BiW9033) 3Bi6 (OH) 3 (H20) 3V4010] · 25H20 192. 90 7. 81 16. 63K „H [(BiW 9 0 33 ) 3 Bi 6 (OH) 3 (H 2 0) 3 V 4 0 10 ] 25H 2 0 192.90 7.81 16.63
K12 [ (VO) 3 (PW9034) 2] · nH20,„ 489. 71 7. 81 62. 68K 12 [(VO) 3 (PW 9 0 34 ) 2 ] nH 2 0, „489.71 7.81 62.68
Na„ (NH4) [ (Mn (H?0) 1 3 (SbW9033) 2] · 45H,0 500. 72 7. 81 64. 88 Na "(NH 4) [( Mn (H? 0) 1 3 (SbW 9 0 33) 2] · 45H, 0 500. 72 7. 81 64. 88
ACV > 100 く 0. 039 〉2000 表中における 「く」 は表に示した数値よりも大きかったことを表し、 「>」 は表に示した数 値よりも小さかったたことを表す。 また、 「―」 は毒性が強く、 CC;()等を測定できなかつ たことを表す。 ACV> 100 0 0.039 ＞ 2000 In the table, “く” indicates that the value was larger than the value shown in the table, and “>” indicates that the value was smaller than the value shown in the table. “-” Indicates that toxicity was so high that CC ; () could not be measured.
[0029] 表 1に示すように、 Na [SbW O ] · 19.5H Oの抗ウィルス活性は、 ACVに劣るものの  [0029] As shown in Table 1, the antiviral activity of Na [SbWO]
9 9 33 2  9 9 33 2
他のポリ酸ィ匕合物よりも著しく高力つた。また、 Na [SbW O 1- 19.5H Oの細胞毒性は  Strength was remarkably higher than that of other polyacid conjugates. In addition, the cytotoxicity of Na [SbW O 1-19.5H O
9 9 33 2  9 9 33 2
、他のポリ酸ィ匕合物及び ACVよりも低ぐ有効係数は試験物質中の最高値を示した。  However, the effective coefficient lower than that of other polyacid conjugates and ACV showed the highest value among the test substances.
[0030] 本明細書は、本願の優先権の基礎である日本国特許出願 (特願 2004-146114号） の明細書に記載されている内容を包含する。また、本発明で引用した全ての刊行物 、特許および特許出願をそのまま参考として本明細書にとり入れるものとする。 This specification includes the contents described in the specification of the Japanese patent application (Japanese Patent Application No. 2004-146114), which is the basis of the priority of the present application. All publications, patents, and patent applications cited in the present invention are incorporated herein by reference in their entirety.

Claims

請求の範囲 The scope of the claims
[1] 式： [SbW 0 ] で表されるポリ酸イオン、又はその塩を有効成分として含有する抗ゥ  [1] An antibody containing a polyacid ion represented by the formula: [SbW 0] or a salt thereof as an active ingredient.
9 33  9 33
ィルス剤。  Virus.
[2] 式： [SbW 0 ] で表されるポリ酸イオンの塩力 Na [SbW Ο ] · 19.5Η Οである請求  [2] The salt force of the polyacid ion represented by the formula: [SbW 0] Na [SbW Ο] · 19.5Η 請求
9 33 9 9 33 2  9 33 9 9 33 2
項 1記載の抗ウィルス剤。  Item 14. The antiviral agent according to Item 1.
[3] ウィルス力 ヘルぺスウィルスである請求項 1又は 2記載の抗ウィルス剤。 [3] The antiviral agent according to claim 1 or 2, which is a herpes virus.
[4] ヘルぺスウィルスが、単純へルぺスウィルスである請求項 3記載の抗ウィルス剤。 [4] The antiviral agent according to claim 3, wherein the herpes virus is a simple herpes virus.
[5] 単純へルぺスウィルス力 単純へルぺスウィルス 1型である請求項 4記載の抗ウイ ルス剤。  [5] Herpes simplex virus activity The antiviral agent according to claim 4, which is simple herpes virus type 1.
PCT/JP2005/008758 2004-05-17 2005-05-13 Antiviral agent WO2005110443A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004146114A JP2005325083A (en) 2004-05-17 2004-05-17 Antiviral agent
JP2004-146114 2004-05-17

Publications (1)

Publication Number Publication Date
WO2005110443A1 true WO2005110443A1 (en) 2005-11-24

Family

ID=35393992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/008758 WO2005110443A1 (en) 2004-05-17 2005-05-13 Antiviral agent

Country Status (2)

Country Link
JP (1) JP2005325083A (en)
WO (1) WO2005110443A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013216182B2 (en) * 2012-01-31 2014-10-30 VB JAPAN TECHNOLOGY Co., LTD. Wet hand towel and method for producing the same
CN112055538A (en) * 2018-05-31 2020-12-08 Vb日本技术株式会社 Antibacterial and antiviral composition and aqueous solution

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022097334A1 (en) * 2020-11-04 2022-05-12

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873362A (en) * 1994-09-07 1996-03-19 Poritoronikusu:Kk Anti-mrsa agent
JP2000229864A (en) * 1999-02-08 2000-08-22 Toshihiro Yamase Antiviral agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873362A (en) * 1994-09-07 1996-03-19 Poritoronikusu:Kk Anti-mrsa agent
JP2000229864A (en) * 1999-02-08 2000-08-22 Toshihiro Yamase Antiviral agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHOJI Y ET AL: "Shinki Poly-san Kagobutsu no anti-herpes Koka -Dai 1 ho-.", vol. 52, 1 May 2004 (2004-05-01), pages 118, XP002994217 *
YAMASE T ET AL: "Polyoxomethalate to Ko-Virus Sayo-Muki Iyaku no Jitsugen o Mezashite.", vol. 201, no. 4, 27 April 2002 (2002-04-27), pages 262 - 263, XP002994216 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013216182B2 (en) * 2012-01-31 2014-10-30 VB JAPAN TECHNOLOGY Co., LTD. Wet hand towel and method for producing the same
US20140363520A1 (en) * 2012-01-31 2014-12-11 VB JAPAN TECHNOLOGY Co., LTD. Wet hand towel and method for producing the same
US9332760B2 (en) * 2012-01-31 2016-05-10 VB JAPAN TECHNOLOGY Co., LTD. Wet hand towel and method for producing the same
CN112055538A (en) * 2018-05-31 2020-12-08 Vb日本技术株式会社 Antibacterial and antiviral composition and aqueous solution

Also Published As

Publication number Publication date
JP2005325083A (en) 2005-11-24

Similar Documents

Publication Publication Date Title
JP2020510070A (en) How to treat feline coronavirus infection
US20050031708A1 (en) Composition comprising a zeolite compound for treatment of diseases
JP7522845B2 (en) Use of nucleotide-based compounds in the treatment of coronavirus infections
WO2005110443A1 (en) Antiviral agent
JP2707252B2 (en) Antiviral agent
RU2738719C1 (en) Agent for treating coronavirus, retrovirus infections and hepatitis c
JPS63145279A (en) Drug product
JP4420997B2 (en) Antiviral agent
CN111135166A (en) Pharmaceutical composition consisting of GC376 and GS-441524 and application thereof in inhibiting new coronavirus
JP3121859B2 (en) Antiviral agent
JPH02202823A (en) Antiviral agent of acquired immune deficiency syndrome
EP0338092A1 (en) Anti-hiv agent
JPH05507719A (en) pharmaceutical treatment
EP2851368B1 (en) Complex compounds of germanium, methods for producing same, and drugs
CN109010362A (en) A kind of children's compound electrolyte glucose injection and preparation method thereof
KR101847848B1 (en) Adjuvant composition containing citrulline
EP2257292B1 (en) Zn/trimethoprim combination therapy
WO1990006756A1 (en) Antiviral agent
Mitra et al. Effect of natural compounds to inhibit human respiratory syncytial virus
WO2012091610A1 (en) Drug with activity against the herpes virus family
EP2674415B1 (en) Homo- and hetero-polyamino-acid derivatives of fullerene c60, method for producing same, and pharmaceutical compositions based on said derivatives
EP3720440A1 (en) Treatment of rsv with combination product
EP0500905B1 (en) Pharmaceutical compositions for use in treating aids
US20010007857A1 (en) Method for treating feline immunodefiency virus infections
EP2777700A1 (en) Method for ingesting creatine composition, creatine composition for use in said ingestion method, and creatine-containing medicinal agent and food each produced using said creatine composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase